These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 617785)

  • 1. Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX.
    Chung KS; Goldsmith JC; Roberts HR
    Bibl Haematol; 1977; 44():68-74. PubMed ID: 617785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
    Noyes CM; Griffith MJ; Roberts HR; Lundblad RL
    Proc Natl Acad Sci U S A; 1983 Jul; 80(14):4200-2. PubMed ID: 6603618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.
    Chung KS; Madar DA; Goldsmith JC; Kingdon HS; Roberts HR
    J Clin Invest; 1978 Nov; 62(5):1078-85. PubMed ID: 711853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
    Bertina RM; van der Linden IK
    Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The abnormal factor IX of hemophilia B+ variants.
    Bertina RM; Veltkamp JJ
    Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
    Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
    J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
    Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
    J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and function of factor IX: defects in haemophilia B.
    McGraw RA; Davis LM; Lundblad RL; Stafford DW; Roberts HR
    Clin Haematol; 1985 Jun; 14(2):359-83. PubMed ID: 3899439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
    Bertina RM; Van Der Linden IK
    J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
    de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
    Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
    Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Takahashi H; Iwanaga S
    J Biochem; 1988 Dec; 104(6):878-80. PubMed ID: 3243764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of canine factor IX.
    Sugahara Y; Catalfamo J; Brooks M; Hitomi E; Bajaj SP; Kurachi K
    Thromb Haemost; 1996 Mar; 75(3):450-5. PubMed ID: 8701406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
    Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
    Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
    Sakai T; Yoshioka A; Yamamoto K; Niinomi K; Fujimura Y; Fukui H; Miyata T; Iwanaga S
    J Biochem; 1989 May; 105(5):756-9. PubMed ID: 2753873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
    Wu PC; Hamaguchi N; Yu YS; Shen MC; Lin SW
    Thromb Haemost; 2000 Oct; 84(4):626-34. PubMed ID: 11057861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw.
    Liddell MB; Lillicrap DP; Peake IR; Bloom AL
    Br J Haematol; 1989 Jun; 72(2):208-15. PubMed ID: 2788012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine.
    Chao H; Walsh CE
    Thromb Haemost; 1999 Oct; 82(4):1378. PubMed ID: 10544943
    [No Abstract]   [Full Text] [Related]  

  • 19. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
    Herzog RW; Arruda VR; Fisher TH; Read MS; Nichols TC; High KA
    Thromb Haemost; 2000 Aug; 84(2):352-4. PubMed ID: 10959714
    [No Abstract]   [Full Text] [Related]  

  • 20. A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
    Taylor SA; Liddell MB; Peake IR; Bloom AL; Lillicrap DP
    Br J Haematol; 1990 Jun; 75(2):217-21. PubMed ID: 2372509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.